These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 19832978)
1. The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Varesio L BMC Genomics; 2009 Oct; 10():474. PubMed ID: 19832978 [TBL] [Abstract][Full Text] [Related]
2. Identification of multiple hypoxia signatures in neuroblastoma cell lines by l1-l2 regularization and data reduction. Fardin P; Cornero A; Barla A; Mosci S; Acquaviva M; Rosasco L; Gambini C; Verri A; Varesio L J Biomed Biotechnol; 2010; 2010():878709. PubMed ID: 20652058 [TBL] [Abstract][Full Text] [Related]
3. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Versteeg R; Caron HN; Molenaar JJ; Ora I; Eva A; Puppo M; Varesio L Mol Cancer; 2010 Jul; 9():185. PubMed ID: 20624283 [TBL] [Abstract][Full Text] [Related]
4. Artificial neural network classifier predicts neuroblastoma patients' outcome. Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577 [TBL] [Abstract][Full Text] [Related]
5. Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients. Cangelosi D; Muselli M; Parodi S; Blengio F; Becherini P; Versteeg R; Conte M; Varesio L BMC Bioinformatics; 2014; 15 Suppl 5(Suppl 5):S4. PubMed ID: 25078098 [TBL] [Abstract][Full Text] [Related]
6. A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation. Wang C; Tan J; Jin Y; Li Z; Yang J; Jia Y; Xia Y; Gong B; Dong Q; Zhao Q Front Immunol; 2024; 15():1415736. PubMed ID: 38962012 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional adaptation of neuroblastoma cells to hypoxia. Fredlund E; Ovenberger M; Borg K; Påhlman S Biochem Biophys Res Commun; 2008 Feb; 366(4):1054-60. PubMed ID: 18155155 [TBL] [Abstract][Full Text] [Related]
8. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Tawk B; Schwager C; Deffaa O; Dyckhoff G; Warta R; Linge A; Krause M; Weichert W; Baumann M; Herold-Mende C; Debus J; Abdollahi A Radiother Oncol; 2016 Feb; 118(2):350-8. PubMed ID: 26711490 [TBL] [Abstract][Full Text] [Related]
10. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Applebaum MA; Jha AR; Kao C; Hernandez KM; DeWane G; Salwen HR; Chlenski A; Dobratic M; Mariani CJ; Godley LA; Prabhakar N; White K; Stranger BE; Cohn SL Oncotarget; 2016 Nov; 7(47):76816-76826. PubMed ID: 27765905 [TBL] [Abstract][Full Text] [Related]
11. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858 [TBL] [Abstract][Full Text] [Related]
12. In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer. Abu-Jamous B; Buffa FM; Harris AL; Nandi AK Mol Cancer; 2017 Jun; 16(1):105. PubMed ID: 28619028 [TBL] [Abstract][Full Text] [Related]
13. A NOTCH3 transcriptional module induces cell motility in neuroblastoma. van Nes J; Chan A; van Groningen T; van Sluis P; Koster J; Versteeg R Clin Cancer Res; 2013 Jul; 19(13):3485-94. PubMed ID: 23649002 [TBL] [Abstract][Full Text] [Related]
14. Identification of gene signatures from RNA-seq data using Pareto-optimal cluster algorithm. Mallik S; Zhao Z BMC Syst Biol; 2018 Dec; 12(Suppl 8):126. PubMed ID: 30577846 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors. Ognibene M; Cangelosi D; Morini M; Segalerba D; Bosco MC; Sementa AR; Eva A; Varesio L PLoS One; 2017; 12(11):e0187206. PubMed ID: 29117193 [TBL] [Abstract][Full Text] [Related]
16. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214 [TBL] [Abstract][Full Text] [Related]
17. Gene Expression Signatures as Biomarkers of Tumour Hypoxia. Harris BH; Barberis A; West CM; Buffa FM Clin Oncol (R Coll Radiol); 2015 Oct; 27(10):547-60. PubMed ID: 26282471 [TBL] [Abstract][Full Text] [Related]
18. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300 [TBL] [Abstract][Full Text] [Related]
19. Double Selection Based Semi-Supervised Clustering Ensemble for Tumor Clustering from Gene Expression Profiles. Yu Z; Chen H; You J; Wong HS; Liu J; Li L; Han G IEEE/ACM Trans Comput Biol Bioinform; 2014; 11(4):727-40. PubMed ID: 26356343 [TBL] [Abstract][Full Text] [Related]
20. Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures. Pfeil J; Sanders LM; Anastopoulos I; Lyle AG; Weinstein AS; Xue Y; Blair A; Beale HC; Lee A; Leung SG; Dinh PT; Shah AT; Breese MR; Devine WP; Bjork I; Salama SR; Sweet-Cordero EA; Haussler D; Vaske OM PLoS Comput Biol; 2020 Apr; 16(4):e1007753. PubMed ID: 32275708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]